Price T Rowe Associates Inc Keros Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,187,910 shares of KROS stock, worth $78.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,187,910
Previous 1,218,504
2.51%
Holding current value
$78.9 Million
Previous $80.7 Million
32.7%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding KROS
# of Institutions
157Shares Held
27.5MCall Options Held
28.7KPut Options Held
1.8K-
Black Rock Inc. New York, NY2.51MShares$167 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$117 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.6MShares$106 Million0.12% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.53MShares$101 Million8.43% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.27MShares$84.3 Million1.4% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.71B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...